Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROGEL-VAGINAL vs METRO I.V. IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Treatment of bacterial vaginosis (FDA-approved),Off-label: Trichomoniasis, anaerobic bacterial infections
Treatment of intra-abdominal infections (peritonitis, intra-abdominal abscess),Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (amebic dysentery and amebic liver abscess),Treatment of skin and skin structure infections (decubitus ulcers, infected wounds),Treatment of gynecologic infections (endometritis, tubo-ovarian abscess),Treatment of central nervous system infections (meningitis, brain abscess),Treatment of septicemia and endocarditis,Off-label: Perioperative prophylaxis for colorectal surgery,Off-label: Treatment of Helicobacter pylori infection (combined with other agents),Off-label: Crohn's disease (perianal fistulas)
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Hepatic metabolism via oxidation and glucuronidation; major metabolite: hydroxy-metronidazole (active).
Hepatic metabolism via oxidation and glucuronidation, primarily by CYP450 enzymes (CYP2A6, CYP3A4). The major metabolites are hydroxymetronidazole and metronidazole glucuronide.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
<20% bound; primarily to serum albumin (minimal binding)
<20% bound to plasma proteins
0.25-0.85 L/kg (widely distributed to tissues, including vaginal mucosa and cerebrospinal fluid)
0.25-0.85 L/kg; indicates wide distribution into tissues including CSF
Intravaginal: Systemic bioavailability approximately 50-60% relative to oral; vaginal absorption variable (mean ~56% of oral dose)
100% intravenous
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use with caution.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Hemodialysis: dose after dialysis.
No specific Child-Pugh based adjustments available. Use with caution in severe hepatic impairment due to potential metronidazole accumulation.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% (e.g., 500 mg every 12 h).
Safety and efficacy not established in pediatric patients; data insufficient for weight-based dosing.
Neonates (GA <34 wk): 7.5 mg/kg every 12 h; (GA ≥34 wk): 7.5 mg/kg every 8 h. Infants/children: 10 mg/kg every 6-8 h. Max 4 g/day.
No specific dose adjustment required. Use standard dosing with consideration of age-related decline in renal function and potential for concurrent medications.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Monitor for neurotoxicity.
No FDA boxed warning.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use should be avoided.
Carcinogenicity: Avoid unnecessary prolonged use; rodent studies showed tumorigenicity.,Peripheral neuropathy: May occur with high doses or prolonged therapy.,Candidiasis: May overgrow Candida; treat concurrent infections.,Neutropenia: Monitor CBC if retreatment needed.,Alcohol interaction: Disulfiram-like reaction (abdominal cramps, nausea, vomiting) if alcohol consumed within 48 hours.,Hepatic impairment: Use with caution; dose adjustment may be needed.
May cause seizures and peripheral neuropathy; discontinue if neurologic symptoms occur.,Use caution in patients with central nervous system disorders.,Blood dyscrasias: Use with caution in patients with history of or current blood dyscrasias.,Hepatic impairment: Dose adjustment may be required.,Carcinogenicity: Avoid prolonged or unnecessary use.,Drug interactions: Potentiation of anticoagulant effect of warfarin; disulfiram-like reaction with alcohol.,Prolonged QT interval: Use with caution with QT-prolonging agents.,Superinfection: May cause overgrowth of Clostridioides difficile.
Hypersensitivity to metronidazole or nitroimidazoles,Pregnancy: Contraindicated in first trimester (use only if clearly needed in second/third trimester),Use with alcohol or propylene glycol,Use with disulfiram (within 2 weeks)
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (relative contraindication; use only if clearly needed),Breastfeeding (manufacturer recommends discontinuation of nursing or drug, but AAP considers compatible),Use with disulfiram (within 2 weeks of disulfiram administration),Use with alcohol or propylene glycol-containing products (due to disulfiram-like reaction)
Avoid alcohol and any products containing alcohol (e.g., certain sauces, vinegars, desserts, mouthwashes) during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions.
Avoid alcohol and any foods or beverages containing alcohol (e.g., beer, wine, liquor, some vinegars, certain desserts) for 48 hours after last dose. No other significant food interactions.
Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations, but some studies suggest a possible association with cleft lip/palate; use only if clearly needed. In the second and third trimesters, no increased risk of fetal abnormalities has been reported. Avoid use in preterm labor or premature rupture of membranes due to potential systemic absorption.
Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies suggest a possible small risk of cleft palate. The CDC and FDA consider it contraindicated in the first trimester unless clearly needed. In the second and third trimesters, it is generally considered safe, but caution is advised near term due to potential neonatal accumulation.
Metronidazole is excreted in breast milk; after vaginal administration, systemic absorption is minimal (approximately 2% of oral dose), resulting in low milk concentrations. The M/P ratio is approximately 0.8-1.0 for oral dosing; for vaginal gel, ratio is expected lower. The American Academy of Pediatrics considers single-dose therapy compatible with breastfeeding after timed dosing and discarding milk for 12-24 hours. For chronic use, monitor infant for gastrointestinal disturbances.
Metronidazole is excreted into breast milk with milk-to-plasma ratio of approximately 0.6-1.0. Peak milk concentrations occur 2-4 hours after dose. The American Academy of Pediatrics considers it compatible with breastfeeding, but some sources advise discarding milk for 12-24 hours after a single high dose (2 g) to reduce infant exposure. For standard dosing, benefits likely outweigh risks.
No dose adjustment is required for METROGEL-VAGINAL during pregnancy. Systemic absorption is low (<2%), and pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) do not necessitate dose modification for vaginal administration. Use standard dosage: one applicatorful (5 g containing 37.5 mg metronidazole) intravaginally once or twice daily for 5 days.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic clearance) may reduce serum concentrations of metronidazole, but the clinical significance is unclear. No dose adjustment is routinely recommended; however, for serious infections, therapeutic drug monitoring may be considered. Standard dosing (e.g., 500 mg IV every 8 hours) is typically used.
Metronidazole vaginal gel is first-line for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Use caution in patients with Cockayne syndrome due to risk of severe hepatotoxicity. May cause metallic taste. Do not use during menstruation; treatment is typically 5 days but can be extended to 7-10 days for recurrent BV.
Metronidazole IV exhibits excellent bioavailability; oral and IV dosing are equivalent. Avoid ethanol-containing medications or diet due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use. Adjust dose in severe hepatic impairment (Child-Pugh C).
Use the applicator to insert the gel into the vagina as directed, usually once or twice daily for 5 days.,Do not drink alcohol or use alcohol-containing products (mouthwash, cough syrup) during treatment and for 2 days after stopping.,You may notice a metallic taste in your mouth, which is common and harmless.,Avoid sexual intercourse or use condoms during treatment to prevent irritation and reinfection.,Wash hands before and after use. Do not use tampons, douches, or other vaginal products during therapy.
Do not consume alcohol or products containing propylene glycol during treatment and for at least 48 hours after completion.,Report any numbness, tingling, or burning in hands or feet immediately.,Complete the full course as prescribed even if symptoms improve.,May cause metallic or bitter taste; this is temporary and harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROGEL-VAGINAL vs METRO I.V. IN PLASTIC CONTAINER, answered by our medical review team.
METROGEL-VAGINAL is a Antibiotic (Nitroimidazole) that works by Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.. METRO I.V. IN PLASTIC CONTAINER is a Antibiotic (Nitroimidazole) that works by Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROGEL-VAGINAL and METRO I.V. IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROGEL-VAGINAL is: One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.. The standard adult dose of METRO I.V. IN PLASTIC CONTAINER is: IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROGEL-VAGINAL and METRO I.V. IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROGEL-VAGINAL is classified as Category C. Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations,. METRO I.V. IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies sugges. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.